Lilly and Boehringer cut German investments amid health-spending overhaul
read at Endpoints ↗RegulatoryNegative
A proposed overhaul of Germany's health-insurance financing is sparking criticism from industry groups.
Eli Lilly and Boehringer Ingelheim announced they will reduce their investment programmes in the country in response to the plan.
The cuts come as the government seeks to curb health-spending growth, raising concerns about the impact on research, production and jobs in the German pharma sector.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly, Boehringer retrench in Germany on proposed health spending cuts”
read at Endpoints ↗83 words · retrieved Jun 4
comments(0)
5-min edit window · permanent after that